Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity Completed Phase Trials for Gefitinib (DB00317)

IndicationStatusPhase
DBCOND0029503 (Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00068497Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerTreatment